(Enibarcimab)Biosimilar Reference Antibody-GS40227

货号：GS40227

Enibarcimab (development code Adrecizumab) is an investigational, humanized monoclonal antibody developed for the treatment of acute and critical conditions involving vascular dysfunction. It functions as a neutralizing agent against the peptide hormone Adrenomedullin (ADM). Specifically, it is designed to bind and neutralize the bioactive, free form of ADM in the bloodstream, while not interfering with its precursor or bound forms. This targeted neutralization is believed to protect the vascular endothelial barrier, reduce excessive vasodilation, and help maintain vascular integrity during severe systemic stress, thereby counteracting pathological processes associated with circulatory shock and organ dysfunction.